Tags

Type your tag names separated by a space and hit enter

[Therapeutic procedures in gastroesophageal reflux disease].
Z Gastroenterol. 1986 Sep; 24 Suppl 2:40-4.ZG

Abstract

The medical therapy of reflux esophagitis consists of modifications of the patients's lifestyle and antacids, alginic acid or both (phase I). Phase II medications include drugs that suppress acid/peptic activity (antacid/alginate, H2-receptor blockers, cimetidine, ranitidine, famotidine), drugs that enhance motility (metoclopramide, domperidone) and drugs that coat and increase mucosal protection (sucralfate). Combinations of H2-receptor blockers and motility stimulating drugs have not been very effective. Overall the results of medical therapy of reflux esophagitis are suboptimal.

Authors

No affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

2877526

Citation

Tytgat, G N.. "[Therapeutic Procedures in Gastroesophageal Reflux Disease]." Zeitschrift Fur Gastroenterologie, vol. 24 Suppl 2, 1986, pp. 40-4.
Tytgat GN. [Therapeutic procedures in gastroesophageal reflux disease]. Z Gastroenterol. 1986;24 Suppl 2:40-4.
Tytgat, G. N. (1986). [Therapeutic procedures in gastroesophageal reflux disease]. Zeitschrift Fur Gastroenterologie, 24 Suppl 2, 40-4.
Tytgat GN. [Therapeutic Procedures in Gastroesophageal Reflux Disease]. Z Gastroenterol. 1986;24 Suppl 2:40-4. PubMed PMID: 2877526.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Therapeutic procedures in gastroesophageal reflux disease]. A1 - Tytgat,G N, PY - 1986/9/1/pubmed PY - 2000/6/1/medline PY - 1986/9/1/entrez SP - 40 EP - 4 JF - Zeitschrift fur Gastroenterologie JO - Z Gastroenterol VL - 24 Suppl 2 N2 - The medical therapy of reflux esophagitis consists of modifications of the patients's lifestyle and antacids, alginic acid or both (phase I). Phase II medications include drugs that suppress acid/peptic activity (antacid/alginate, H2-receptor blockers, cimetidine, ranitidine, famotidine), drugs that enhance motility (metoclopramide, domperidone) and drugs that coat and increase mucosal protection (sucralfate). Combinations of H2-receptor blockers and motility stimulating drugs have not been very effective. Overall the results of medical therapy of reflux esophagitis are suboptimal. SN - 0044-2771 UR - https://www.unboundmedicine.com/medline/citation/2877526/[Therapeutic_procedures_in_gastroesophageal_reflux_disease]_ L2 - http://www.diseaseinfosearch.org/result/2996 DB - PRIME DP - Unbound Medicine ER -